HALO

Business Context and Reporting Period

Company: HALOZYME THERAPEUTICS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: Halozyme is a biopharmaceutical company developing products targeting the extracellular matrix, primarily utilizing its proprietary recombinant human hyaluronidase enzyme (rHuPH20). The company operates through two marketed products (HYLENEX and Cumulase) and key strategic partnerships with Roche and Baxter to apply its Enhanze Technology to biological therapeutics.

Key Financial Metrics

Liquidity: As of March 31, 2010, the company held approximately $55.2 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next twelve months, with an anticipated net cash burn of $40.0 to $45.0 million for the full year 2010.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased by approximately $669,000 (24%) compared to the first quarter of 2009. This was driven by a $320,000 increase in product sales (primarily due to increased HYLENEX sales following its Q4 2009 launch) and a $350,000 increase in collaborative agreement revenues.
• Expense Reduction: Operating expenses decreased by approximately $2.3 million. Research and Development (R&D) expenses dropped $2.5 million (18%) due to reduced manufacturing activities and clinical trial costs for the ultrafast insulin program. Selling, General, and Administrative (SG&A) expenses increased slightly by $0.3 million, largely due to higher stock compensation.
• Improved Net Loss: The net loss narrowed by approximately $2.9 million year-over-year, primarily attributable to the reduction in operating expenses.
• Cash Flow Deterioration: Net cash used in operating activities increased significantly from $3.8 million to $12.6 million. This was primarily due to a $9.9 million decrease in receipts from partnership payments compared to the prior year, partially offset by lower operating expenses.

Outlook, Risks, and Management Commentary

Guidance and Outlook:

• Management anticipates total net cash burn of $40.0 to $45.0 million for the year ending December 31, 2010.
• Product sales are expected to increase in future periods due to the commercial launch of HYLENEX.
• R&D expenses are expected to increase as product candidates advance into later stages of clinical development.
• The company filed a shelf registration statement in January 2010 allowing for the sale of up to $100.0 million of equity or debt securities to fund future operations.

Key Risks and Contingencies:

• Profitability: The company has incurred net operating losses since inception and may never achieve profitability. Revenues are currently insufficient to fund operations.
• Regulatory Approval: Future revenues depend on obtaining FDA and other regulatory approvals for proprietary and partnered product candidates, which is uncertain and costly.
• Partnership Dependence: The business relies heavily on key partners (Roche, Baxter) for development, manufacturing, and commercialization. Failure of partners to perform or termination of agreements could materially harm the company.
• Manufacturing Risks: The company relies on contract manufacturers (Avid Bioservices and Cook Pharmica) for API production. Any failure to scale up or maintain cGMP status could delay clinical trials or commercialization.
• Intellectual Property: The company faces risks related to the protection and enforcement of its patents, as well as potential infringement claims from third parties.

Unusual Items:

• Share-Based Compensation: Total share-based compensation expense was $1.2 million for the quarter, allocated between R&D and SG&A.
• Deferred Revenue: Significant deferred revenue ($59.3 million total) exists due to upfront payments and license fees from Roche and Baxter partnerships, which are recognized over time.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $55.2 million cash balance against the projected $40-45 million annual burn rate and potential delays in clinical milestones.
• Partnership Milestones: Monitor the progress of Roche's Phase 3 subcutaneous Herceptin trial and Baxter's Phase 3 GAMMAGARD LIQUID trial, as these drive future milestone payments.
• HYLENEX Commercialization: Assess the actual sales volume of HYLENEX post-launch to validate revenue growth projections.
• Manufacturing Capacity: Confirm the status of Cook Pharmica's cGMP approval and ability to scale API production for commercial needs.
• Capital Needs: Evaluate the likelihood and terms of future equity or debt financing required to fund operations beyond the next 12 months.